# Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients

> **NCT02784756** · NA · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 134 (actual)

## Conditions studied

- Cytomegalovirus Viraemia

## Interventions

- **DEVICE:** Quantiferon-CMV assay

## Key facts

- **NCT ID:** NCT02784756
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2020-02
- **Final completion:** 2020-04
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2022-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02784756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02784756, "Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02784756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*